Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TTFields and Pulsed Bevacizumab in Bevacizumab-refractory Recurrent GBM
NCT02663271Phase 2Terminated
- Sponsor
- University of Florida
- Start
- Dec 2016
- Primary completion
- Jun 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in glioblastoma (GBM), sponsored by University of Florida. Started Dec 2016; status: terminated.
02
Drugs
bevacizumab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02663271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02663271.